It is suggested that circ-MTHFD1L may be a new potential molecular marker for chemotherapy resistance of pancreatic cancer gemcitabine and a potential therapeutic target for combined treatment with olaparib. The gene discussed is MTHFD1L; the disease is familial pancreatic carcinoma.